Itrop

Itrop is a bronchodilator belonging to the group of m-anticholinergics, produced in Germany by Boehringer Ingelheim. The active substance of the drug is ipratropium bromide, also known under the synonyms Arutropid, Atrovent, Atrovent N, Vagos and Ipravent.

The drug is available as film-coated tablets containing 10 mg ipratropium bromide and as an injection solution containing 0.5 mg/ml ipratropium bromide. Itrop is used to treat chronic obstructive bronchitis, bronchial asthma, hyperproduction of sputum and bronchial obstruction due to colds.

Contraindications to the use of the drug include hypersensitivity to ipratropium bromide. Restrictions on use include angle-closure glaucoma, urinary disorders due to prostatic hypertrophy, breastfeeding and pregnancy.

Itrop can cause some side effects, including cough, very rarely - paradoxical bronchospasm, rash, urticaria, dry mouth, headache, nausea, accommodation disturbance (if in contact with the eyes) and dry mouth.

Itrop enhances the bronchodilator effect of beta-agonists and xanthine derivatives, and also enhances the anticholinergic effect of other drugs. In case of overdose of the drug, no specific symptoms have been identified, however, some manifestations of systemic anticholinergic action are possible, such as dry mouth, impaired accommodation and increased heart rate. Treatment of overdose is symptomatic.

Thus, Itrop is an effective remedy for the treatment of bronchial diseases, but before using it, you need to familiarize yourself with contraindications and restrictions for use, and also consult a doctor to avoid side effects and unwanted interactions with other drugs.